Aurinia Pharmaceuticals Inc $AUPH Shares Bought by Fox Run Management L.L.C.

Key Points

• Fox Run Management L.L.C. increased its stake in Aurinia Pharmaceuticals by 122.7%, acquiring a total of 44,962 shares valued at approximately $361,000.
• Other notable institutional investors, including LPL Financial and Wells Fargo, also boosted their positions in Aurinia Pharmaceuticals during the fourth quarter.
• Aurinia Pharmaceuticals reported a Q2 EPS of $0.16, slightly missing forecasts, with revenue of $70.01 million, exceeding expectations.

Fox Run Management L.L.C. increased its stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 122.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 44,962 shares of the biotechnology company's stock after purchasing an additional 24,777 shares during the quarter. Fox Run Management L.L.C.'s holdings in Aurinia Pharmaceuticals were worth $361,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Tang Capital Management LLC raised its holdings in Aurinia Pharmaceuticals by 16.6% during the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company's stock valued at $75,697,000 after acquiring an additional 1,200,000 shares during the period. Nuveen Asset Management LLC raised its holdings in Aurinia Pharmaceuticals by 10.2% during the fourth quarter. Nuveen Asset Management LLC now owns 1,492,301 shares of the biotechnology company's stock valued at $13,401,000 after acquiring an additional 138,054 shares during the period. Nuveen LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at about $10,014,000. Northern Trust Corp raised its holdings in Aurinia Pharmaceuticals by 5.9% during the fourth quarter. Northern Trust Corp now owns 1,054,365 shares of the biotechnology company's stock valued at $9,468,000 after acquiring an additional 58,676 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at about $7,630,000. 36.83% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Kevin Tang acquired 200,000 shares of the firm's stock in a transaction on Tuesday, August 5th. The stock was acquired at an average price of $11.68 per share, for a total transaction of $2,336,000.00. Following the completion of the transaction, the director owned 11,329,500 shares in the company, valued at approximately $132,328,560. The trade was a 1.80% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired 1,300,000 shares of company stock valued at $13,590,000 over the last 90 days. 12.20% of the stock is currently owned by corporate insiders.

Aurinia Pharmaceuticals Stock Up 0.6%

Shares of AUPH stock traded up $0.07 during trading hours on Thursday, reaching $12.08. 1,004,563 shares of the company's stock were exchanged, compared to its average volume of 2,797,342. The stock's 50 day moving average is $9.39 and its 200-day moving average is $8.50. The company has a market cap of $1.59 billion, a price-to-earnings ratio of 28.09 and a beta of 1.23. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a fifty-two week low of $6.42 and a fifty-two week high of $12.53.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million for the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on AUPH shares. HC Wainwright restated a "buy" rating and set a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Royal Bank Of Canada lifted their price target on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $12.00.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.